ORGANIZATION

October 2019 “Only Option” for Drug Price Revision Tied to Sales Tax Hike: New FPMAJ Chief

September 25, 2018
The new leader of the umbrella organ of Japanese pharma trade groups has expressed the industry’s opposition to a two-step price tweak in 2019 that the government eyes for the planned consumption tax hike in October that year, pushing for…

To read the full story

Related Article

ORGANIZATION

By Reiji Anasako

Kyowa Hakko Kirin’s first and only Rituxan (rituximab) biosimilar in Japan is showing a faster-than-expected uptake in the market, with the company racking up 4.3 billion yen from the cancer drug in 2018, far beyond its initial 3.2 billion yen…

Members of a key reimbursement policy panel appear to be becoming more and more open to the industry’s call for…

By Philip Carrigan

With a cursory glance, recruitment is easily defined. We’re here to help place candidates into the vacancies our clients need to fill. Armed with a pen and paper, you could even map out the process.• We study the market• We…

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…